Search and Filter
Results per Page: 20
  • 5
  • 10
  • 20
  • 50
  • 100
Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection

Newly defined biomarker may accelerate clinical trials for vaccines to prevent HIV-1 infection

A study published in the Aug. 22, 2022 issue of Nature Medicine identifies a new biomarker that appears effective as a surrogate endpoint to reliably predict the ability of broadly neutralizing monoclonal antibodies to prevent acquisition of HIV-1, the most common type of the virus that causes AIDS.
News Releases - August 24, 2022
HVTN at the 24th International AIDS Conference in Montreal

HVTN at the 24th International AIDS Conference in Montreal

HVTN researchers and faith leaders will address HIV and SARS-CoV-2, neutralizing antibodies, future directions for research, lessons from COVID-19 community engagement, overcoming HIV stigma and discrimination, and more
News Releases - July 28, 2022
CoVPN Trial: Novavax’s Traditional COVID-19 Vaccine Correlates to Strong Antibody Response, Protection Against SARS-CoV-2

CoVPN Trial: Novavax’s Traditional COVID-19 Vaccine Correlates to Strong Antibody Response, Protection Against SARS-CoV-2

Response comparable to mRNA vaccines and if authorized, could help bolster global vaccine supplies
News Releases - June 28, 2022
Antibody Mediated Prevention (AMP) Trials Data Published by the New England Journal of Medicine

Antibody Mediated Prevention (AMP) Trials Data Published by the New England Journal of Medicine

Most advanced clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains
News Releases - March 17, 2021